Follicular fluid is the liquid bath inside each ovarian follicle, and it is far more than a passive ultrafiltrate of blood plasma. It is a dynamic biological compartment formed through selective transfer of circulating constituents across the blood-follicle barrier together with secretory products generated locally by the oocyte, cumulus cells, granulosa cells and theca cells. Its composition integrates systemic endocrine inputs with bidirectional oocyte-somatic cell communication, steroidogenesis, metabolic coupling, extracellular-matrix remodeling, periovulatory inflammation, redox homeostasis, mitochondrial function and angiogenesis. In effect, follicular fluid is a molecular record of the follicle’s physiological state, and because it is aspirated during every IVF cycle, it offers a minimally invasive window into the microenvironment that shaped each egg.

The review, led by researchers at China Medical University Hospital in Taiwan, synthesizes mechanistic and clinical evidence on follicular-fluid biomarkers associated with oocyte maturity, fertilization, embryo development, blastocyst formation, implantation and live birth. Particular attention goes to granulosa cell-associated signaling networks involving epidermal growth factor-like ligands, pentraxin 3, transforming growth factor-beta and bone morphogenetic protein family members, activins and follistatin, cytokines, steroid hormones, metabolic intermediates, lipids, oxidative-damage markers and extracellular-matrix components. Among these candidates, the steroid hormones progesterone and anti-Müllerian hormone measured in individual follicles have the most direct observational evidence, with associations reported for fertilization, embryo morphology, blastocyst development and even live birth after fresh single-embryo transfer.

Yet the review’s central conclusion is sobering: no single molecule in follicular fluid has demonstrated sufficient reproducibility, discrimination and calibration to support routine clinical prediction. The reasons are deeply rooted in follicular biology. Growth factors are pleiotropic and context-dependent, so the biological significance of one concentration cannot be interpreted independently of related ligands, receptors, binding proteins and downstream signaling activity. Functional redundancy within the transforming growth factor-beta superfamily means that alterations in one molecule may be compensated for by changes elsewhere in the network, so an apparently normal value does not necessarily indicate normal pathway activity. Follicular signaling is also temporally and spatially organized, meaning that concentrations measured at retrieval represent a time-specific composite influenced by follicle size, maturation status, ovarian stimulation, trigger regimen and the interval between triggering and aspiration.

Methodological heterogeneity compounds the problem. Patient phenotype, ovarian-stimulation regimen, follicular stage, sampling strategy, preanalytical handling, analytical platform and outcome definition all influence measured concentrations. Follicular heterogeneity and the statistical non-independence of multiple oocytes obtained from the same patient further complicate biomarker evaluation, because several follicles from one woman are biologically correlated rather than independent observations. Within-patient variability in follicular-fluid estradiol has been reported to be approximately twice the between-patient variability, underscoring how pooling fluid from multiple follicles obscures follicle-specific signals and prevents reliable linkage between a biochemical measurement and its corresponding oocyte or embryo.

The authors therefore propose a decisive transition from single-analyte measurements toward mechanism-informed, outcome-specific multianalyte panels that integrate follicular-fluid measurements with cumulus-cell or granulosa-cell transcriptomic, proteomic, metabolomic and lipidomic features. Phenotype-specific models, particularly for polycystic ovary syndrome, may further improve biological interpretation. Advanced mass-spectrometry approaches such as SWATH, a data-independent acquisition method that sequentially isolates and fragments precursor ions across predefined mass-to-charge windows, can improve analytical coverage and reproducibility for low-abundance endogenous metabolites that traditional techniques miss. A preliminary SWATH-based study identified elevated free fatty acids, 3-hydroxynonanoyl carnitine, eicosapentaenoic acid, deoxycorticosterone, phenylalanine and leucine, together with reduced lysophosphatidylcholines and phytosphingosine, in follicular fluid from women with polycystic ovary syndrome, suggesting disturbances in fatty-acid oxidation, phospholipid turnover, amino-acid metabolism and steroidogenesis.

Several biologically coherent modules emerge as promising panel foundations. Periovulatory epidermal growth factor signaling, captured by amphiregulin, reflects luteinizing hormone-induced activation of cumulus expansion and prostaglandin synthesis. Pentraxin 3, an essential structural component of the cumulus extracellular matrix, integrates stimulatory EGF-like signaling with inhibitory inputs from BMP4, BMP7, BMP6, activin A, GDF8 and TGF-beta1, making it a downstream convergence point rather than a readout of a single pathway. The activin-follistatin balance, the progesterone-to-estradiol ratio, redox markers such as glutathione and 8-hydroxy-2′-deoxyguanosine, cell-free mitochondrial DNA, acylcarnitines and lysophosphatidylcholines each represent complementary biological domains. An integrated blastocyst panel could combine metabolic function, mitochondrial or oxidative injury, and follicular-cell support in a single signature.

Clinical translation, however, demands far more than biological plausibility. The review specifies that progress will require standardized individual-follicle sampling, one-to-one linkage between biomarkers and oocyte or embryo outcomes, targeted assay development with documented accuracy, precision, linearity, recovery, stability and matrix effects, multilevel statistical modeling that accounts for follicles nested within women, independent prospective validation across different populations and laboratory platforms, and demonstration of incremental clinical utility beyond established patient and embryological variables. Mechanistic plausibility, clinical association and predictive utility must be regarded as distinct levels of evidence, because experimental changes in gene or protein expression in cultured granulosa-lutein cells do not necessarily produce corresponding changes in follicular-fluid concentrations.

The ultimate goal is a parsimonious and reproducible biomarker panel that complements, rather than replaces, conventional embryological assessment and supports more individualized IVF decision-making. Because follicular fluid is obtained only after follicular aspiration, its most plausible near-term role is research, prognostic assessment or prioritization of sibling oocytes and embryos rather than modification of the ongoing stimulation cycle. Until analytical validity, external reproducibility, clinical utility, feasibility and cost-effectiveness are demonstrated, the proposed combinations should remain investigational. Still, the vision is compelling: a small, interpretable, clinically scalable molecular readout of each follicle’s inner life, finally giving embryologists a way to see not just what an egg looks like, but what it is made of.

Subject of Research: Follicular fluid biomarkers for IVF outcome prediction

Article Title: Integrative follicular fluid biomarkers for oocyte competence and IVF outcomes: from molecular networks to multianalyte panels

Article References: Chen, C.-Y., Lu, Y.-T., Chang, P.-H., Chen, H.-J., Hsueh, Y.-W., Chang, C.-W., Hsu, H.-C., Yang, T.-C., Chang, Y.-Y., & Chang, H.-M. (2026). Integrative follicular fluid biomarkers for oocyte competence and IVF outcomes: from molecular networks to multianalyte panels. Frontiers in Endocrinology, 17, Article 1962631. https://doi.org/10.3389/fendo.2026.1962631

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1962631

Keywords: IVF, follicular fluid, biomarkers, oocyte competence, reproductive medicine, embryology, omics, Integrative, follicular, fluid, oocyte, competence